SCHEMBL2290872

SCHEMBL2290872

O=C(O)c1cnn2cc(-c3ccc(F)cc3)ccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.48
JAK1 P23458 6/20 0.45
JAK3 P52333 6/20 0.45
BCL2L1 Q07817 1/20 0.43
BAD Q92934 1/20 0.43
JAK2 O60674 4/20 0.41
TYK2 P29597 4/20 0.41
KCNH2 Q12809 1/20 0.41
RAB9A P51151 2/20 0.40
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
KDR P35968 1/20 0.39
USP30 Q70CQ3 2/20 0.38
MAP3K5 Q99683 1/20 0.37
F2 P00734 1/20 0.37
PLAU P00749 1/20 0.37
KLKB1 P03952 1/20 0.37
ELANE P08246 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2288826 0.88 JAK1 (0.45) KDM4EJAK1JAK3JAK2TYK2
SCHEMBL3093126 0.88 JAK2 (0.48) JAK1JAK3JAK2TYK2
SCHEMBL1290740 0.87 KDM4E (0.42) KDM4EJAK1JAK3RAB9ANPC1
SCHEMBL2287940 0.87 JAK1 (0.44) KDM4EJAK1JAK3BCL2L1BAD
SCHEMBL3321508 0.83 SLC6A4 (0.47) KDM4EJAK1JAK3JAK2TYK2
SCHEMBL2293381 0.83 JAK1 (0.42) KDM4EJAK1JAK3JAK2TYK2
SCHEMBL2294889 0.80 ALDH1A1 (0.53) KDM4ERAB9ANPC1ALDH1A1SMN1; SMN2
SCHEMBL30363245 0.79 USP30 (0.54) USP30HAT1EP300
SCHEMBL10185277 0.78 MKNK1 (0.51) JAK1JAK3JAK2TYK2ALDH1A1
SCHEMBL14743514 0.74 JAK3 (0.48) KDM4EJAK1JAK3ALDH1A1USP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2114941-B1 BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS ASTEX THERAPEUTICS LTD (GB) 2015-03-25 EP disclosed
US-8518911-B2 Pyrazolo[1,5-a]pyridines as MARK inhibitors MERCK SHARP & DOHME CORP. (US) 2013-08-27 US disclosed
EP-2320737-B1 PYRAZOLO-[1,5-A]-PYRIDINES AS MARK INHIBITORS MERCK SHARP & DOHME (US) 2013-07-17 EP disclosed
US-20110195933-A1 PYRAZOLO[1,5-A]PYRIDINES AS MARK INHIBITORS MERCK SHARP & DOHME LLC 2011-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195933-A1 PYRAZOLO[1,5-A]PYRIDINES AS MARK INHIBITORS MARK3, MARK4, MARK1 KDM4E 406/4885JAK1 521/4885JAK3 619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.